Flight Operations of Two Rapidly Assembled CubeSats with Commercial Infrared Cameras: The Rogue-Alpha,Beta Program

The Aerospace Corporation’s Rogue-alpha, betaprogram, co-funded by the Space and Missile Systems Center’s Development Corps, is a rapid prototyping effort that built and launched two 3-Unit CubeSats equipped with modified commercial IR camera payloads, laser communications and precision pointing capabilities in 18-months. Launched on 2 November 2019, the two spacecraft were released from the ISS Cygnus NG-12 robotic resupply spacecraft on 31 January 2020 into a circular 460-km, 52° inclined orbit. The two Rogue spacecraft are serving as testbeds for studying wide-field-of-view fast-framing imaging, on-orbit stellar calibration techniques for small IR payloads, and associated spacecraft flight operations. Precision pointing is enabled by three star sensors. High data rate sensor observations are enabled by the ultra-compact 200 Mbps lasercom system, which downlinks gigabytes of stored data during a single laser contact, using The Aerospace Corporation’s prototype ground stations located in El Segundo, California. The Rogue-alpha, beta IR sensor is a 1.4 micron band, 640x512 pixel, 28° field of view, InGaAs SWIR camera. It is accompanied by a panchromatic, 10-megapixel, 37° field of view visible context camera. Modes of sensor operation have included: 1) horizon-pointed imaging in all directions relative to the spacecraft orbit (fore, aft, port, and starboard) which is designed to maximize the imaged field of view, 2) point-and-stare imaging, 3) nadir-pointed, and 4) stereo fore-aft pointing using both spacecraft. All of these modes of operation are usually conducted in multi-frame collections at 1-20hz for dozens to thousands of frames. Highlights from the Rogue-alpha, beta sensor Earth remote sensing observation experiments will be presented. These have included impressive video imagery of hurricanes, typhoons, thunderstorms, and high clouds in the intra-tropical convergence zone. Infrared and visible point sources studied include gas flares, wildfires, active volcanos, nighttime lights, and other phenomena, including the first infrared CubeSat observations of space launch upper stages in flight. Stereo cloud imaging observations were also conducted with an aim of better understanding Earth backgrounds from low Earth orbit. Highlights from the CubeSat flight operations experiments include: 1) spacecraft-to-spacecraft boresight alignment of Rogue’s lasercom systems, and 2) metric and radiometric calibration of Rogue’s flight cameras using bright infrared stars. The results from the Rogue-alpha, beta460-km orbit show the exciting possibilities for wide-field-of-view missions from low earth orbit

The InterLACE study: design, data harmonization and characteristics across 20 studies on women's health

The International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events (InterLACE) project is a global research collaboration that aims to advance understanding of women's reproductive health in relation to chronic disease risk by pooling individual participant data from several cohort and cross-sectional studies. The aim of this paper is to describe the characteristics of contributing studies and to present the distribution of demographic and reproductive factors and chronic disease outcomes in InterLACE

Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies

Current evidence on the association between body mass index (BMI) and age at menopause remains unclear. We investigated the relationship between BMI and age at menopause using data from 11 prospective studies. A total of 24,196 women who experienced menopause after recruitment was included. Baseline BMI was categorised according to the WHO criteria. Age at menopause, confirmed by natural cessation of menses for ≥ 12 months, was categorised as < 45 years (early menopause), 45–49, 50–51 (reference category), 52–53, 54–55, and ≥ 56 years (late age at menopause). We used multinomial logistic regression models to estimate multivariable relative risk ratios (RRRs) and 95% confidence intervals (CI) for the associations between BMI and age at menopause. The mean (standard deviation) age at menopause was 51.4 (3.3) years, with 2.5% of the women having early and 8.1% late menopause. Compared with those with normal BMI (18.5–24.9 kg/m2), underweight women were at a higher risk of early menopause (RRR 2.15, 95% CI 1.50–3.06), while overweight (1.52, 1.31–1.77) and obese women (1.54, 1.18–2.01) were at increased risk of late menopause. Overweight and obesity were also significantly associated with around 20% increased risk of menopause at ages 52–53 and 54–55 years. We observed no association between underweight and late menopause. The risk of early menopause was higher among obese women albeit not significant (1.23, 0.89–1.71). Underweight women had over twice the risk of experiencing early menopause, while overweight and obese women had over 50% higher risk of experiencing late menopause

An index to assess the health and benefits of the global ocean

The ocean plays a critical role in supporting human well-being, from providing food, livelihoods and recreational opportunities to regulating the global climate. Sustainable management aimed at maintaining the flow of a broad range of benefits from the ocean requires a comprehensive and quantitative method to measure and monitor the health of coupled human–ocean systems. We created an index comprising ten diverse public goals for a healthy coupled human–ocean system and calculated the index for every coastal country. Globally, the overall index score was 60 out of 100 (range 36–86), with developed countries generally performing better than developing countries, but with notable exceptions. Only 5% of countries scored higher than 70, whereas 32% scored lower than 50. The index provides a powerful tool to raise public awareness, direct resource management, improve policy and prioritize scientific research.This is the publisher’s final pdf. The published article is copyrighted by the Nature Publishing Group and can be found at: http://www.nature.com/nature/index.htm

The acute physiological effects of high- and low-velocity resistance exercise in older adults

The aim of the present study was to determine if workload matched, high-velocity (HVE) and low-velocity (LVE) resistance exercise protocols, elicit differing acute physiological responses in older adults. Ten older adults completed three sets of eight exercises on six separate occasions (three HVE and three LVE sessions). Systolic blood pressure, diastolic blood pressure and blood lactate were measured pre- and post-exercise, heart rate was measured before exercise and following each set of each exercise. Finally, a rating of perceived exertion was measured following each set of each exercise. There were no significant differences in blood lactate (F(1,9) = 0.028; P = 0.872; ηP2 = 0.003), heart rate (F(1,9) = 0.045; P = 0.837; ηP2 = 0.005), systolic blood pressure (F(1,9) = 0.023; P = 0.884; ηP2 = 0.003) or diastolic blood pressure (F(1,9) = 1.516; P = 0.249; ηP2 = 0.144) between HVE and LVE. However, LVE elicited significantly greater ratings of perceived exertion compared to HVE (F(1,9) = 13.059; P = 0.006; ηP2 = 0.592). The present workload matched HVE and LVE protocols produced comparable physiological responses, although greater exertion was perceived during LVE

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570